designed supramolecular nanoparticle (SMNP) vectors for codelivery of CRISPR/Cas9 and RS1 gene, presenting a potential non-viral therapeutic solution for X-linked juvenile retinoschisis (XLRS) (67). This evidence concerns the gene RS1 and X-linked retinoschisis.